Drug Trial Radar · NCT01707381
BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Last checked: Nov 20, 2026Latest source record: Sep 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Nov 2012
Primary completion
Dec 2013
Study completion Feb 2014
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Oct 16, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical investigation is being performed to compare the effect of BOL-303259-X dosed once daily (QD) with timolol maleate 0.5% dosed twice daily (BID) in reducing intraocular pressure (IOP) measured over a 24-hour period in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Conditions
- Ocular Hypertension
- Open Angle Glaucoma
Interventions
BOL-303259-XDrug
Topical ophthalmic solution
Timolol maleateDrug
Topical ophthalmic solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- 24 Hour IOPTime frame: after 4 weeks of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California San Diego
La Jolla, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.